nach oben

Clinical and Experimental Nephrology

Erschienen in:

01.08.2008 | Review Article

Peritoneal damage by peritoneal dialysis solutions

verfasst von: Takafumi Ito, Noriaki Yorioka

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Continuous ambulatory peritoneal dialysis is a well-accepted treatment for end-stage renal disease, but its long-term success is limited. Peritoneal sclerosis is still one of the most important complications of long-term peritoneal dialysis and the low biocompatibility of peritoneal dialysis solutions plays a major role in the development of such sclerosis. In this review, we summarize recent experimental data about the biocompatibility of peritoneal dialysis solutions.

Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif. 1989;7:74–85.CrossRef

Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial. 2002;18:119–23.PubMed

Jörres A, Gahl GM, Frei U. Peritoneal dialysis fluid biocompatibility: does it really matter? Kidney Int. 1994;48:79–86.

Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1991;18:97–102.CrossRef

Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant. 1999;14:1541–9.CrossRef

Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol. 2002;13:480–9.PubMed

Wong TY, Szeto CC, Lai KB, Lam CW, Lai KN, Li PK. Longitudinal study of peritoneal membrane function in continuous ambulatory peritoneal dialysis: relationship with peritonitis and fibrosing factors. Perit Dial Int. 2000;20:679–85.PubMed

Davies SJ. Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrol Dial Transplant. 2006;21:ii47–50.CrossRef

Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrider M, Lage C, et al. The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66:408–18.CrossRef

10.

Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int. 2005;25:248–55.PubMed

11.

Gokal R. Recent perspectives on peritoneal dialysis. Contrib Nephrol. 1993;102:98–109.CrossRef

12.

Rosenberg ME. Peritoneal dialysis: diabetes of the peritoneal cavity. J Lab Clin Med. 1999;134:103–4.CrossRef

13.

Wong TYH, Phillips AO, Witowski J, Topley N. Glucose-mediated induction of TGF-β and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int. 2003;63:1404–16.CrossRef

14.

Kumano K, Schiller B, Hjelle JT, Moran J. Effect of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Blood Purif. 1996;14:165–9.CrossRef

15.

Gotloib L, Waisbrut V, Shostak A, Kushnier R. Acute and long-term change observed in imprints of mouse mesothelium exposed to glucose enriched, lactate buffered dialysis solution. Nephron. 1995;70:466–77.CrossRef

16.

Ito T, Yorioka N, Yamamoto M, Kataoka K, Yamakido M. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol. 2000;11:1969–79.PubMed

17.

Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int. 1992;41:1280–5.CrossRef

18.

Gabrielson EW, Gerwin BI, Harris CC, Roberts AB, Sporn MB, Lechner JF. Stimulation of DNA synthesis in cultured primary human mesothelial cells by specific growth factors. FASEB J. 1988;2:2717–21.CrossRef

19.

Takazoe K, Nakayama M, Utsunomiya Y, Osaka N, Hasegawa H, Kubo H, et al. Detection of TGF-β1 in CAPD effluents. Clin Nephrol. 1997;47:67–9.PubMed

20.

Wang T, Chen YG, Ye RG, Li SL, Li HQ, Chen YX. Effect of glucose on TGF-β1 expression in peritoneal mesothelial cells. Adv Perit Dial. 1995;11:7–10.PubMed

21.

Lai KN, Lai KB, Szeto CC, Lam CWK, Leung JCK. Growth factors in continuous ambulatory peritoneal dialysis effluent. Am J Nephrol. 1999;19:416–22.CrossRef

22.

Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2005;16:425–36.CrossRef

23.

Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effect on membrane function. J Am Soc Nephrol. 2001;12:2029–39.PubMed

24.

Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long term peritoneal dialysis. J Am Soc Nephrol. 2000;11:717–28.PubMed

25.

Thoralley PJ, Johal C, Dobler D, Babaei-Jadidi R, Ahmed N. Concentration of glucose degradation products, glyoxal, methylglyoxal and 3-deoxyglucosone, in current generation peritoneal dialysis fluids determined by liquid chromatography–tandem mass spectrometry (LC–MS/MS). J Am Soc Nephrol. 2005;16:268A.

26.

Nagy JA. Peritoneal membrane morphology and function. Kidney Int. 1996;56:S2–11.

27.

Simionescu M, Simionescu N. Organization of cell junctions in the peritoneal mesothelium. J Cell Biol. 1977;74:98–110.CrossRef

28.

Nagy JA, Jackman RW. Anatomy and physiology of the peritoneal membrane. Semin Dial. 1998;11:49–56.CrossRef

29.

Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321–9.CrossRef

30.

Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol. 1993;3:1531–40.PubMed

31.

Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635–58.CrossRef

32.

Bouzegrhane F, Thibault G. Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res. 2002;53:304–12.CrossRef

33.

Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int. 2001;21:219–24.PubMed

34.

Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol. 2003;14:873–80.CrossRef

35.

Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes. 1999;48:2066–73.CrossRef

36.

Malhotra A, Kang BP, Cheung S, Opawumi D, Meggs LG. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin. Diabetes. 2001;50:1918–26.CrossRef

37.

Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005;25:38–47.PubMed

38.

Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int. 2005;25:483–91.PubMed

39.

Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK 1/2 and p38 MAPK. Kidney Int. 2005;67:1126–35.CrossRef

40.

Sauter M, Clemens D, Wörnle M, Mussack T, Ladurner R, Sitter T. ACE inhibitor and Ata-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int. 2006;22:167–72.

41.

Sitter T, Spannag M, Schiffi H, Held E, van Hinsbergh VWM, Kooistra T. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients. The role of mesothelial cells. Nephrol Dial Transplant. 1995;10:677–83.PubMed

42.

Shao JC, Yorioka N, Nishida Y, Yamakido M. Effect of pH and glucose on cultured human peritoneal mesothelial cells. Scand J Urol Nephrol. 1999;33:248–56.CrossRef

43.

Sitter T, Mandl-Weber S, Wornle M, Haslinger B, Goedde M, Kooistra T. D-Glucose increases the synthesis of tissue-type plasminogen activator (t-PA) in human peritoneal mesothelial cells. Thromb Haemost. 1999;82:1171–6.PubMed

44.

Sitter T, Toet K, Fricke H, Schffi H, Held E, Kooistra T. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. Am J Physiol. 1996;271:R1256–63.CrossRef

45.

Geoddle M, Sitter T, Schiffl H, Bechtel U, Schramm W, Spannagl M. Coagulation- and fibrinolysis-related antigens in plasma and dialysate of CAPD patients. Perit Dial Int. 1997;17:121–4.

46.

Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial. 2005;9:173–81.CrossRef

47.

Hung Y, Noble N. An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney Int. 2005;67:2502–3.CrossRef

48.

Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest. 2002;110:1525–38.CrossRef

49.

Katsutani M, Ito T, Masaki T, Kohno N, Yorioka N. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK 1/2. Ther Apher Dial. 2007;11:94–100.CrossRef

50.

Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchange. Lancet. 1987;ii:178–82.CrossRef

51.

DeFijter CW, Verbrugh HA, Oe LP, Heezius E, Donker AJ, Verhoef J, et al. Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis. 1993;21:411–8.CrossRef

52.

Mistry CD, Gokal R, Peers E, the MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int. 1994;46:496–503.CrossRef

53.

Thomas S, Schnek U, Fischer FP, Metang T, Passlick-Deetjen J, Kuhlmann U. In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis. 1007;29:246–53.CrossRef

54.

Ito T, Yorioka N, Kyuden Y, Asakimori Y, Kiribayashi K, Ogawa T, et al. Effect of glucose polymer on the intercellular junctions of cultured human peritoneal mesothelial cells. Nephron Clin Pract. 2003;93:c97–105.CrossRef

55.

Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, et al. Effect of dwell time on carbonyl stress using icodextirn and amino acid peritoneal dialysis fluids. Kidney Int. 2000;58:2518–24.CrossRef

56.

Kuriyama R, Tranaeus A, Ikegami T. Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients. Adv Perit Dial. 2006;22:108–10.PubMed

57.

Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int. 2005;67:1609–15.CrossRef

58.

Topley N, Kaur D, Peterson MM, Jörres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cells and neutrophil function. Kidney Int. 1996;49:1447–56.CrossRef

59.

Floge J, Eng E, Lindner V, Alpers CE, Young BA, Reidy MA, et al. Rat glomerular mesangial cells synthesize basic fibroblast growth factor: release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest. 1992;90:2362–9.CrossRef

60.

Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 2000;57:1521–38.CrossRef

61.

Jinno K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T. Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol. 1997;32:119–21.CrossRef

62.

Ogata S, Naito T, Yorioka N, Kiribayashi K, Kuratsune M, Kohno N. Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor. Nephrol Dial Transplant. 2004;19:2831–7.CrossRef

63.

Topley N, Alobaidi HMM, Davies M, Coles GA, Williams JD, Lloyd D. The effects of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int. 1988;34:404–1.CrossRef

64.

Coles GA, Lewis SL, Williams JD. Host defence and effects of solutions on peritoneal cells. In: Gokal R, Nolph KD, editors. Textbook of peritoneal dialysis. The Netherlands: Kluwer Academic Publishers, 1994, p. 503–8.CrossRef

65.

Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int. 1992;12:14–27.PubMed

66.

Wieslander AP, Kjellstrand PT, Rippe B. Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Perit Dial Int. 1995;15:S52–9.PubMed

67.

Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen L, et al. In vitro formation of N^ε-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun. 2001;980:1408–14.CrossRef

68.

Kjellstrand P, Erixon M, Wieslander A, Linden T, Martinson E. Temperature: the single most important factor for degradation of glucose fluids during storage. Perit Dial Int. 2004;24:385–91.PubMed

69.

Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Gunita F, et al. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int. 2004;24:392–8.PubMed

70.

Wieslander AP, Nordin MK, Martinson E, Kjellstrand PT, Boberg UC. Heat-sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol. 1993;39:343–9.PubMed

71.

Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Fei U, et al. Effects of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000;11:729–39.PubMed

72.

Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett. 1999;463:260–4.CrossRef

73.

Leung JCK, Chan LYY, Li FFK, Tang SCW, Chan KW, Chan TM, et al. Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrol Dial Transplant. 2005;20:1336–49.CrossRef

74.

Shimizu H, Ishibashi Y, Kumagai T, Kaname S, Fujita T, Sai K, et al. Long-term effect of peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration on peritoneum: a case report. Perit Dial Int. 2007;27:92–4.PubMed

75.

Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. The serum concentration of advanced glycation end product N^ε-(carboxymethyl) lysine is increased in uremia. Kidney Int. 1997;52:1064–7.CrossRef

76.

Freidlander MA, Wu YC, Monnier VM. Kinetics of formation of advanced glycosylation end products (AGEs) in peritoneal dialysis (PD). J Am Soc Nephrol. 1994;5:A447.

77.

Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997;51:182–6.CrossRef

78.

Nishida Y, Shao JC, Kiribayashi K, Nakamura C, Yorioka N. Advanced glycation end-products reduce the viability of human peritoneal mesothelial cells. Nephron. 1998;80:477–8.CrossRef

79.

Ogata S, Yorioka N, Nishida Y, Shao JC, Yamakido M. Expression of receptor for advanced glycation end product mRNA by human peritoneal mesothelial cells. Nephron. 2000;86:245–6.CrossRef

80.

Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int. 2002;61:570–8.CrossRef

81.

Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int. 2003;23:213–21.PubMed

82.

Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxidation products. Nephrol Dial Transplant. 2004;19:2208–16.CrossRef

83.

Vriese ASD, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uremia. Nephrol Dial Transplant. 2006;21:2549–55.CrossRef

84.

Nakamura S, Tachikawa T, Tobita K, Miyazaki S, Sakai S, Morita T, et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis. 2003;41:S61–7.CrossRef

Titel: Peritoneal damage by peritoneal dialysis solutions
verfasst von: Takafumi Ito
Noriaki Yorioka
Publikationsdatum: 01.08.2008
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 4/2008
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-008-0032-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Peritoneal damage by peritoneal dialysis solutions

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Oxalate nephropathy with a granulomatous lesion due to excessive intake of peanuts

Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease

Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy

Serum cystatin C measured by a sol particle homogeneous immunoassay can accurately detect early impairment of renal function

Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure

Aldosterone and glomerular podocyte injury

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin